Open-label, Cross-over Study of IM and IV Doses of SPL026 in Healthy, Psychedelic-experienced Participants (Part A: IM and IV Doses) and Participants With Little to no Psychedelic Experience (Part B: IM Dose Only)
Latest Information Update: 25 Mar 2024
At a glance
- Drugs N-N-dimethyltryptamine (Primary) ; N-N-dimethyltryptamine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Small Pharma
Most Recent Events
- 28 Jun 2023 Status changed from active, no longer recruiting to completed as per Small Pharma media release.
- 28 Jun 2023 Results published in Small Pharma media release
- 14 Apr 2023 Status changed from recruiting to active, no longer recruiting.